Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02216409 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody
A Phase 1 study of Solid Tumor, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 88
- Enrollment target
- 6
- Study locations
NCT02216409: Completed Phase 1 study of Solid Tumor, sponsored by Gilead Sciences.
NCT02216409 is a Phase 1 study of Solid Tumor that has completed, run by Gilead Sciences. The registered enrollment target is 88 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (60% lower). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02216409, a Phase 1 study of Solid Tumor, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 88 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of this study is to assess the safety and tolerability of Hu5F9-G4 in participants with solid tumors.
Primary Outcome
The CTCAE criteria will be used to assess adverse events on this trial.
Conditions Studied
Interventions
- DRUG Hu5F9-G4
Study Locations (6)
California
- Stanford Cancer Institute - Stanford
Illinois
- University of Chicago - Chicago
Michigan
- START Midwest - Grand Rapids
New York
- Memorial Sloan-Kettering Cancer Center - New York
Oklahoma
- University of Oklahoma - Oklahoma City
Texas
- South Texas Accelerated Research Therapeutics - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2014-08 |
| Est. Completion | 2018-12 |
| Phase | Phase 1 |
What the finished NCT02216409 record still lists
NCT02216409 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 88 participants, a relatively small participant target, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (60% lower).
The record links to 1 condition, with Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which Hu5F9-G4 is the first listed.
NCT02216409 lists 6 locations in 6 states (California, Illinois, Michigan).
Frequently Asked Questions
What is clinical trial NCT02216409 about?
NCT02216409 is a clinical study titled "Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody". The purpose of this study is to assess the safety and tolerability of Hu5F9-G4 in participants with solid tumors.
What is the current status of trial NCT02216409?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 88 participants. The study started on 2014-08. Estimated completion is 2018-12.
What conditions does trial NCT02216409 study?
This clinical trial studies the following conditions: Solid Tumor.
What interventions are being tested in trial NCT02216409?
The interventions under investigation include: Hu5F9-G4 (DRUG).
Who is sponsoring clinical trial NCT02216409?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02216409 being conducted?
This trial has 6 study locations across California, Illinois, Michigan, New York, Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02216409's enrollment target sits among peer trials
88 94th of 196 higher than 103 of 196 other Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03843463 · 88 participants · Phase 2
Escitalopram and Language Intervention for Subacute Aphasia
- NCT04066348 · 88 participants · Phase 2
TNF-α Treatment of Blast-Induced Tinnitus
- NCT04331704 · 88 participants · Phase 4
ANCHORS Alcohol & Sexual Health Study: UH3 Project
- NCT04536103 · 88 participants
Multi-Vendor Multi-Site Novel Accelerated MRI Relaxometry
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia